Codexis Signs License Deal with Novartis

22:48 EDT 16 May 2019 | CHEManager

US protein engineering company Codexis has signed a platform agreement with Novartis, granting the Swiss pharmaceutical producer a non-exclusive license to its proprietary CodeEvolver protein technology. Novartis will use the license to develop novel performance enzymes for use in drug manufacture. Upon completion of the technology transfer, the CodeEvolver protein engineering platform will be located at an undisclosed Novartis site.

Original Article: Codexis Signs License Deal with Novartis


More From BioPortfolio on "Codexis Signs License Deal with Novartis"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...